RS Oncology's New Aggressive Cancer Treatment Data Chosen for ASCO Oral Presentation

RS Oncology, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for aggressive and rare cancers, has announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will present comprehensive Phase 1 dose escalation data from its MITOPE multicenter study, which focuses on the safety and tolerability of RSO-021, a pioneering therapy aimed at treating mesothelioma and solid tumors in patients with malignant pleural effusion (MPE).

The MITOPE Phase 1 trial is the first human study of RSO-021, which functions as a first-in-class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3). This trial is crucial for evaluating the potential of RSO-021 in addressing aggressive cancers that manifest as MPE, a condition where cancer spreads to the pleural space, significantly reducing life expectancy. Renowned oncology expert, Professor Dean Fennell from Leicester Hospitals Trust in the UK, will present the detailed dose escalation data during a rapid oral session, followed by a moderated panel discussion to answer related questions.

Aggressive cancers pose significant challenges in their treatment and management due to their fast growth and tendency to metastasize. MPE is a prime example of such complications, often arising from cancers like mesothelioma, lung, breast, and ovarian cancers, and even from the spread of cancer from organs including the stomach, kidneys, ovaries, and colon. The ongoing Phase 2 extension of the MITOPE study is currently being conducted in the UK. This phase explores the efficacy of RSO-021 both as a standalone treatment and in conjunction with other therapies for stage IV metastatic cancers associated with MPE.

The second phase of the trial aims to provide more comprehensive data on the potential benefits of RSO-021 in treating these severe conditions. Dr. Sean Dulloo from the University of Leicester will deliver an update on the progress of the MITOPE Phase 2 trial in the form of a poster presentation. This presentation will occur during the Lung Cancer session, providing insights into the trial's current status and its future directions.

The release of this data is highly anticipated, with a publication embargo in place until 5:00 PM (EDT) on Thursday, May 23, 2024, as enforced by ASCO.

Detailed information about the presentations includes:

Rapid Oral Abstract Presentation
- Title: "First-in-human phase 1 clinical trial of RSO-021, a first-in-class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE)."
- Presenter: Professor Dean Fennell
- Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
- Date/Time: Monday, June 3, 9:06 am (session from 8:00-9:30 am)
- Abstract #3019

Poster Presentation
- Title: "Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor."
- Presenter: Dr. Sean Dulloo
- Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
- Date/Time: Monday, June 3, from 1:30 - 4:30 PM CDT
- Abstract #TPS8124
- Poster Board: #381b

RS Oncology is dedicated to advancing scientific discoveries and fostering global collaborations to enhance the lives of patients battling aggressive cancers. The company’s participation in the ASCO Annual Meeting underscores its commitment to transparency and scientific rigor in its pursuit of innovative cancer treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!